GLP-1 receptor expression and beta-cell mass in patients with type 2 diabetes

GLP-1 receptor expression and beta-cell mass in patients with type 2 diabetes - GLP1R-T2D

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55656

Enrollment

Registered

2018-07-12

Start date

2021-02-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus type 2 Diabetes type 2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Scheduled for partial or complete pancreatectomy at Radboudumc

Exclusion criteria

Exclusion criteria: 1.. Breast feeding, 2. Pregnancy or the wish to become pregnant within 6 months, 3. Creatinine clearance below 40ml/min, 4. Age > 18 years, 5. Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range, 6. Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors in the past 3 months

Design outcomes

Primary

Measure	Time frame
- AIM 1: Establish the relation between exendin uptake and BCM under various levels of glycaemic control - AIM2: Assess the specificity of exendin uptake during the progression of T2D	—

Secondary

Measure	Time frame
- AIM 3: Establish the relation between BCM and beta-cell function in patients with T2D - AIM 4: Correlate ex vivo exendin uptake in GLP-1R positive tissues with GLP-1R gene expression profiles	—

Countries

Netherlands

Outcome results